Patient Satisfaction and Quality of Life Impact - PecFent®
NCT01698645 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2013-07-11
Summary
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
Conditions
- Breakthrough Cancer Pain
Interventions
- DRUG
-
PecFent® (fentanyl) nasal spray
Sponsors & Collaborators
-
Archimedes Development Ltd
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2014-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea
NCT01856114 ·Status: COMPLETED ·Phase: PHASE2
-
Breakthrough Dyspnea Fentanyl Study in Cancer Patients
NCT01515566 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
NCT05272865 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
NCT02210182 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Metabolism Study in Healthy Male Participants
NCT03247283 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
NCT03987555 ·Status: SUSPENDED
-
Evaluation of the Effect of an Specific Oral Nutritional Supplement on the Nutritional Status in Cancer and Malnutrition
NCT04184713 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
NCT03486314 ·Status: COMPLETED ·Phase: PHASE1
-
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
NCT00004154 ·Status: COMPLETED ·Phase: PHASE3
-
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
NCT04188418 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
NCT03459729 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients
NCT05748704 ·Status: RECRUITING ·Phase: NA
-
Corticosteroids for Cancer Pain
NCT00676936 ·Status: COMPLETED ·Phase: PHASE3
-
A Five-Year Quality of Life Study for Cancer Patients
NCT01539148 ·Status: UNKNOWN
-
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
NCT00019656 ·Status: COMPLETED ·Phase: PHASE1
-
Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
NCT02597478 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial
NCT05041946 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
NCT03057366 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacology Study of Aerosolized Liposomal
NCT00250120 ·Status: WITHDRAWN ·Phase: PHASE2
-
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
NCT00387504 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
NCT02792465 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
NCT00751205 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenomic Testing to Personalize Supportive Oncology
NCT04500301 ·Status: COMPLETED ·Phase: NA
-
Theophylline in Treating Cancer Patients With Shortness of Breath
NCT00003684 ·Status: COMPLETED ·Phase: PHASE3